Menu Search
Equities

Embla Medical hf

EMBLA:CPH

Embla Medical hf

Actions
Health CareMedical Equipment and Services
  • Price (DKK)36.00
  • Today's Change0.10 / 0.28%
  • Shares traded21.23k
  • 1 Year change+29.50%
  • Beta0.5305
Data delayed at least 15 minutes, as of Nov 25 2024 15:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 4 analysts offering 12 month price targets for Embla Medical hf have a median target of 39.94, with a high estimate of 41.52 and a low estimate of 33.36. The median estimate represents a 11.25% increase from the last price of 35.90.
High15.6%41.52
Med11.3%39.94
Low-7.1%33.36

Earnings history & estimates in USD

On Jul 23, 2024, earnings of 0.05 per share. This result was in line with the expectation of the one analyst following the company
The next earnings announcement is expected on Feb 05, 2025.
Average growth rate+32.15%
Embla Medical hf reported annual 2023 earnings of 0.14 per share on Jan 30, 2024.
Average growth rate+147.47%
More ▼

Revenue history & estimates in USD

Ossur hf. had 3rd quarter 2024 revenues of 214.00m. This bettered the 212.00m consensus of the 2 analysts covering the company. This was 18.09% above the prior year's 3rd quarter results.
Average growth rate+2.81%
Ossur hf. had revenues for the full year 2023 of 785.68m. This was 9.33% above the prior year's results.
Average growth rate+3.80%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.